Drug intelligence / Profile preview

insulin + sulfonylurea

Development stage: Unknown
Lead developer: Arecor Therapeutics
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous

Overview

A combination therapy approach using both insulin and sulfonylurea medications to manage type 2 diabetes mellitus. Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, while exogenous insulin supplements the body's natural insulin. This combination provides complementary mechanisms to improve glycemic control when monotherapy is insufficient. The combination carries an increased risk of hypoglycemia and requires careful monitoring.

Other names: sulfonylurea and insulinsulfonylureas plus insulin

Targets

INSR (Insulin receptor)KATP channel (ATP-sensitive potassium channel)

Beyond the preview

Go deeper on insulin + sulfonylurea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin + sulfonylurea.

Explore the full profile